Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study

Zhao, Zijun; Zhang, Ting; Yao, Yu; Lu, Xin

doi:10.1186/s12893-022-01472-8

BMC Surgery

Table 3 Univariable analysis of OS and BCSS in OBC patients

From: Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study

Variables	OS			BCSS
	HR	95% CI	P-value	HR	95% CI	P-value
Age (year)	1.05	1.03–1.06	< 0.0001	1.03	1.02–1.04	< 0.001
< 40	Reference			Reference
40–49	0.63	0.31–1.31	0.22	0.82	0.34–1.97	0.66
50–59	0.93	0.49–1.77	0.83	0.99	0.44–2.20	0.98
60–69	1.14	0.60–2.16	0.68	1.10	0.50–2.45	0.81
≥ 70	2.69	1.44–5.01	0.002	2.03	0.93–4.46	0.08
Race
White	Reference			Reference
Black	1.30	0.93–1.81	0.12	0.88	0.55–1.42	0.61
Asian or Pacific Islander	0.75	0.44–1.26	0.28	0.37	0.15–0.89	0.03
American Indian/Alaska Native	1.11	0.28–4.49	0.88	1.78	0.44–7.17	0.42
Unknown/other	8.34 × 10^–7	0-INF	0.99	7.65 × 10⁻⁷	0-INF	0.99
Marital status
Not married	Reference			Reference
Married	0.71	0.56–0.91	0.007	0.77	0.56–1.06	0.11
Unknown	1.25	0.69–2.26	0.47	1.31	0.63–2.72	0.47
Grade
I/II	Reference			Reference
III	2.59	1.03–6.54	0.04	2.59	1.03–6.54	0.04
IV	0.99	0.12–8.52	1.00	0.99	0.12–8.52	1.00
Unknown	1.81	0.74–4.42	0.20	1.81	0.74–4.42	0.20
Laterality
Right	Reference			Reference
Left	1.03	0.81–1.31	0.79	1.11	0.82–1.51	0.50
Histology
Ductal carcinoma	Reference			Reference
Lobular carcinoma	0.85	0.44–1.62	0.61	1.24	0.59–2.60	0.57
Mixed type	0.69	0.28–1.70	0.43	0.77	0.24–2.47	0.67
Other	0.85	0.66–1.08	0.18	1.03	0.75–1.43	0.84
N
N1mi	Reference			Reference
N1	2.15	0.53–8.70	0.28	1.01	0.32–16.46	0.41
N2	2.84	0.69–11.67	0.15	1.01	0.64–33.65	0.13
N3	4.00	0.98–16.32	0.05	1.01	1.04–54.08	0.05
No. of positive LN
1–3	Reference			Reference
4–9	1.82	1.32–2.52	< 0.001	2.77	1.79–4.28	< 0.001
≥ 10	2.22	1.59–3.10	< 0.001	4.42	2.91–6.71	< 0.001
Other/Unknown	1.01	1.99–3.77	< 0.001	4.09	2.67–6.25	< 0.001
Stage
IB	Reference			Reference
IIA	2.15	0.53–8.70	0.28	1.01	0.32–16.46	0.4123
IIIA	2.84	0.69–11.63	0.15	1.01	0.63–33.51	0.1312
IIIC	4.02	0.98–16.40	0.05	1.01	1.04–54.37	0.0453
Surgery
BCS	Reference			Reference
Mastectomy	0.82	0.53–1.26	0.36	1.08	0.60–1.94	0.80
None/Unknown	1.13	0.76–1.69	0.55	1.44	0.82–2.52	0.20
Radiation
None/Unknown	Reference			Reference
Yes	0.66	0.52–0.84	0.0007	0.70	0.52–0.95	0.02
Chemotherapy
Yes	Reference			Reference
No/Unknown	0.55	0.43–0.71	< 0.001	0.73	0.52–1.02	0.07
Type of systemic therapy
Neoadjuvant	Reference			Reference
Adjuvant	0.97	0.61–1.55	0.91	0.92	0.53–1.60	0.76
Neoadjuvant + adjuvant	0.53	0.24–1.15	0.11	0.73	0.32–1.66	0.45
Only systemic therapy, no surgery	3.42	1.71–6.83	0.0005	3.58	1.61–7.97	0.002
Other	0.27	0.37–1.08	0.09	0.52	0.27–1.04	0.06
No/Unknown	0.25	1.01–2.70	0.04	1.39	0.76–2.53	0.28
Subtypes
Luminal A	Reference			Reference
Luminal B	0.62	0.30–1.27	0.19	0.69	0.28–1.66	0.40
HER2 positive	1.31	0.70–2.43	0.40	1.80	0.89–3.64	0.10
Triple negative	1.63	1.03–2.57	0.04	2.03	1.17–3.54	0.01
Unknown	1.28	0.91–1.81	0.16	1.52	0.98–2.35	0.06
ER
Negative	Reference			Reference
Borderline/Unknown	1.08	0.73–1.61	0.70	1.18	0.73–1.90	0.50
Positive	0.71	0.55–0.92	0.009	0.59	0.43–0.81	0.001
PR
Negative	Reference			Reference
Borderline/Unknown	1.08	0.76 -1.56	0.66	1.06	0.68–1.66	0.80
Positive	0.78	0.60–1.01	0.06	0.54	0.38–0.77	0.0007
HER2
Negative	Reference			Reference
Positive	0.74	0.46–1.19	0.21	0.85	0.49–1.47	0.56
Unknown	1.08	0.81–1.43	0.62	1.15	0.81–1.63	0.43

CI confidence interval, ER estrogen receptor, HER-2 human epidermal growth factor receptor-2, N N staging of OBC, PR progesterone receptor

Back to article page

ISSN: 1471-2482

Contact us

Submission enquiries: bmcsurgery@biomedcentral.com
General enquiries: ORSupport@springernature.com